Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Pillar Biosciences, SomaLogic, Dante Labs, More

Pillar Biosciences: Randy Pritchard

Pillar Biosciences has appointed Randy Pritchard as CEO, replacing Gang Song, also the company's founder, who will transition to the role of board chairman. Pritchard has more than 24 years of healthcare experience, including as SVP of US diagnostics marketing; SVP and lifestyle leader in the division of POC Diagnostic and Core Reagents; and VP of marketing at centralized diagnostics at Roche Diagnostics.


SomaLogic: Troy Cox, Kevin Conroy, Steve Quake, Bob Barchi, Ted Meisel

Following its merger with special purpose acquisition company CM Life Sciences II, SomaLogic will add five new directors to its board. Troy Cox is the former CEO of Foundation Medicine and senior VP of US BioOncology for Genentech; Kevin Conroy is the chairman and CEO of Exact Sciences; Steve Quake is professor of bioengineering and applied physics at Stanford University; Bob Barchi is the former president of and a professor at Rutgers University; and Ted Meisel is the executive founder of Avia Health Innovation and executive chairman of WiserCare.


Dante Labs: Sandra Close

Sandra Close has been appointed to the board of directors of Dante Labs. She is the former chief diagnostics strategy officer of Invitae, which she joined in 2020 after Invitae acquired ArcherDx, where she was executive VP of quality, regulatory, and business strategy. Prior to that, she was CEO and an independent consultant at GenEngine.


For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more